Breast Cancer Protocols

Roger Williams Medical Center

Cancer Protocol& Research

Providing patients and health care professionals access to the on-going clinical trials thatare open for patient enrollment

• Services
• for Patients
• for Caregivers
  • Physicians
  • Clinical Trials & Research
  • Nurses/Clinical Staff
  • Residency & Fellowship Programs
• About Us
• Contact Us

• Home ›
• For Caregivers ›
• Clinical Trials & Research ›
• Cancer Protocol Office ›
• Breast Cancer Protocols

Breast Cancer Protocols

• RWH# 300-04: Phase Ia/Ib Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
  
• RWH# 356-45 (Br 211-B): Q3 Week Carboplatin with Weekly Abraxane™ and Trastuzumab as Neoadjuvant Therapy in Resectable and Unresectable (Stage IIA-IIIB) HER2-Positive Breast Cancer: A BrUOG Phase II Study

Contact Information

• Frances D’Allesandro, C.C.R.P. 
  Clinical Research Coordinator, RWMC Protocol Office
  Phone: (401) 456-2698 - Fax: (401) 456-2658 - fdallesandro@chartercare.org
• Jessica Donaghy A.S.
  Administrative Associate, RWMC Protocol Office 
  Phone: (401) 456-5393 - Fax: (401) 456-2658 - jdonaghy@chartercare.org

Cancer Protocol Office

• Overview
• Breast Cancer Protocols
• Prostate Cancer Protocols
• Thoracic, Head & Neck Protocols
• GI Cancer Protocols
• Immunotherapy Protocols
• Supportive Care Protocols
• Bone Marrow Protocols
• Protocol Review Committee
• Resources
• News Briefs